Physician profile
Amanda C Powers
NPI 1588997357
$5,529.05
in general payments reported to CMS, 2019-2025
49 companies · $976 in 2025
The $976 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,151 · 2022: $1,163 · 2023: $1,141 · 2024: $1,098 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,215.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,058.69 | 2021-2025 | |
| Novo Nordisk INC | $574.98 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $436.96 | 2021-2025 | Assurity, Freestyle Libre 3, Eterna |
| Pfizer INC. | $431.23 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $388.24 | 2021-2025 | |
| Glaxosmithkline, LLC. | $342.64 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $244.73 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.67 | 2021-2024 | |
| Daiichi Sankyo INC. | $168.52 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $167.76 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.70 | 2022-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $104.17 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $97.79 | 2022-2024 | Prolia, Evenity, Repatha |
| Dexcom, INC. | $83.26 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $78.29 | 2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.